Abstract-This paper presents a novel microfabricated Boyden chamber in silicon with well-defined pore sizes and controlled membrane thickness for cell migration analysis. The chip-based chamber is fabricated employing lithography and deep reactive ion etching techniques on a double-sided polished silicon wafer. The device contains micro-pores with a silicon oxide layer at the top and a deep microfluidic channel at the bottom, which is anodically-bonded to a glass wafer for sealing and facilitating the imaging and chemoattractant feeding. The applicability of the chip has been demonstrated through the distinct migratory behaviors of highly metastatic breast cancer cells, MDA-MB-231, through pores with 8 µm in diameter, 50 µm in spacing, and 30 µm in thickness. Employing the above technique, the membrane thickness variation among different chips was below 10%. Utilizing this micro-Boyden chamber device, we have shown that MDA-MB-231 cells migrated distinctively in higher rate than the cells which had gone through sphingosine kinase inhibitor drug treatment or no chemoattractant feeding over a course of 12 hours. Furthermore, we validated the performance of the micro-Boyden chamber by quantifying the migration rate of the cancer cells under different chemoattractant gradient profiles.
The insert consists of a porous membrane with a predefined pore size depending on the size of cells to be monitored. Such platforms have been developed to investigate the invasion rate of lung cancer cells [3] , study single tumor cell migration [4] , and examine the effect of specific proteins on brain cancer cells [5] . Additionally, similar platforms have been developed to analyze cell migration by using techniques other than the commercial Boyden chamber products. For instance, the wound healing assay is utilized to measure the rate of cell migration during the repair of a damaged wound [6] , [7] . In another instance, the spheroid migration assay [8] , [9] , is used to monitor the migration behavior of tumor spheroid clusters on 2D surfaces.
With the help of microfabrication techniques, researchers have been able to miniaturize and build targeted applications for commercial in vitro migration and invasion assays. Utilizing soft lithography and gel injection, a microfluidic platform was developed to study the invasion of endothelial and cancer cells through a central channel into the side channels loaded with a chemoattractant [10] , [11] . A microfluidic device with two overlaying channels separated by a commercially available 1μm-porous membrane was developed to model a vascular/valvular three-dimensional environment [12] . This platform was employed to investigate shear stress-regulated paracrine interactions between valvular endothelial cells and valvular interstitial cells. Another microfluidic device was developed in polydimethylsiloxane (PDMS) to quantify the migration and extravasation phenotype of primary tumor cells through a series of 2D planar narrow capillary microchannels [13] . Several other micro-based Boyden chamber devices have been developed mainly by incorporating a commercially available porous membrane to study cell migratory behaviors [14] , [15] In some of the above instances, cell channels are separated by a membrane or a gel layer from the chemoattractant channels. The membrane layer is cut from a commercially available transmigration well and incorporated between the custom fabricated source and chemoattractant channels, which reduces the integration capacity of these systems while increasing the manual labor required for fabrication. In planar devices with parallel channels, although imaging is facilitated, the throughput of the system is limited to less than two simultaneous assays.
So far, silicon has been the material of choice for micromachining. With the help of lithography and dry etching, a wide variety of structures can be fabricated in a controlled and precise fashion on silicon substrates. Deep reactive ion etching (DRIE) has been utilized to construct deep trenches and high aspect ratio through-silicon vias [16] , [17] , arrays of micropillars [18] , and nanowires [19] . In this setting, the etch parameters can be adjusted to control the etch rate, etch directionality, scalloping, and uniformity [20] , [21] . We have used the combination of lithography and DRIE techniques to fabricate a versatile migration assay platform in silicon and tested the performance with cancer cells under control condition and after treatment with anti-tumor drug, sphingosine kinase inhibitor (SKI-I) [22] . Furthermore, we have utilized lithography process for patterning of pores across a single membrane which can be used to adjust the diffusion profile. Then, DRIE is utilized to fabricate a microfluidics-enabled deep micro-channel with a porous thin-membrane on a single silicon wafer with a high level of control on the membranethickness. In this work, we discuss in details the etching parameters and their impacts on the channel fabrication and membrane thickness. Furthermore, we have shown the migration of cells under different chemical gradient by changing the chemical concentration.
II. FABRICATION OF MICRO-ENGINEERED BOYDEN CHAMBER
The fabrication process flow includes the steps to construct the microchannel on the back and the pores on the front of a double-sided polished 300 (±5) μm-thick silicon wafer as shown in Fig. 1 . The pore parameters with r = 4μm and d = 50 were designed and used for lithography on a high resolution chrome mask (The Photoplot Store, CO, USA). To fabricate the pores, SPR 220.3 (Dow Electronic Materials, DE, USA) photoresist is patterned, exposed with vacuum contact using Karl Suss MA-6 mask aligner (Germany), and developed on the silicon wafer. The pores are then etched using the recipe shown in Table 1 by an Alcatel AMS-100 DRIE (France) (Fig. 1.a) . The pores are etched ∼5μm more than the desired membrane thickness to ensure that they are through when the backside channel is etched. Next, a 400nm-thick silicon oxide layer is deposited utilizing PECVD (Orion, AZ, USA) ( Fig. 1.b) . This oxide layer serves as a protection layer when the backside etching of the channel meets the etched pores. It also enables the bonding of PDMS to the device by creating oxygen containing groups on the surface and enhancing cell attachment by producing a hydrophilic surface. Thereafter the thickness of the silicon wafer is measured utilizing a Bruker DektakXT (MA, USA). This measurement is done at this stage to minimize the contamination of silicon wafer prior to the pore fabrication. Next, the wafer is cleaned thoroughly by oxygen plasma (Trion RIE, AZ, USA) and immersed in a nanostrip (Cyanteck, CA, USA) solution, rinsed with di-ionized (DI) water, and dried at 150°C for 15 minutes. The microfluidic channel with the central well is fabricated on the backside of the silicon wafer using backside alignment and DRIE. The central square well and microfluidic channel are 4mm-wide and 1mm-wide, respectively. The photoresist AZ9260 (AZ Electronic Materials, NJ, USA) is patterned, aligned, exposed, and developed to fabricate the microfluidic channel. The silicon from the pore side is spun with SPR220.3 and glued to a clean silicon wafer. The second silicon wafer seals the DRIE substrate and contains the backside cooling helium once the pores are exposed during the channel etching. The microfluidic channels are etched using DRIE by the recipe provided in Table 1 . The etch rate is carefully measured at different etch points to obtain a 30μm-thick membrane (wafers etched for ∼270μm). The glued wafers are immersed in a warm PRS2000 (J. T. Baker, USA) solution for 10 minutes until they are detached. The devices are then cleaned via oxygen plasma and nanostrip rinse and anodically bonded to a 500μm-thick Borofloat 33 glass wafer utilizing the Karl Suss SB6 bonder (Germany) to seal the microfluidic channels. The devices are then diced and each individual device is plasmabonded utilizing an oxygen plasma cleaner (Harrick Plasma, NY, USA) to a thick PDMS with the mixture ratio of 10:1 Sylgard 184 (Dow Corning, MI, USA). Fig. 2a shows the front and back of the micro-Boyden chamber device. Fig. 2b shows (i) the cross-section E-SEM image of the thin porousmembrane and (ii) the top view of the pores with the size and spacing labelled. Employing the above technique and recipe, we achieved ∼1μm (<3%) variation on the membrane thickness across 60% of the wafer area and 3μm (∼10%) across the whole wafer.
III. EXPERIMENTAL METHODS

A. Cell Culture and Preparation
The metastatic human breast cancer cell line, MDA-MB-231 (a gift from Dr. Ayesha Shajahan-Haq, Lombardi Cancer Center, Georgetown University, Washington, DC) was obtained from American Type Culture Collection (ATCC, VA, USA). Cells were maintained in T-25 flasks in Dulbecco's Modified Eagle's Medium (DMEM) (ATCC) containing 10% fetal bovine serum (FBS) (Atlanta Biologicals, GA, USA) and antibiotics, 100 U/ml penicillin and 100μg/ml streptomycin (Mediatech, VA, USA), at 37°C in a humidified 5% CO 2 incubator. Before any kind of treatment, MDA-MB-231 cells were tagged with the fluorescent tag, 5-chloromethylfluorescein diacetate (Cell Tracker Green CMFDA Dye) (Life Technologies, NY, USA) with a working concentration of 5μm in serum-free media in order to visualize and image cells.
Cells below 80% confluency were serum starved overnight in DMEM media without FBS. For drug treatment experiments, cells were treated with SKI-I compound which is known to exhibit antitumor activity [23] , [24] . Cells were incubated with a commercially available SKI compound, 5-(2-Naphthalenyl)-1H-pyrazole-3-carboxylic acid 2-[(2-hydroxy-1-naphthalenyl) methylene]hydrazide (SKI-I, ab142209) (Abcam, MA, USA). SKI-I was dissolved in dimethyl sulfoxide (DMSO) (Life Technologies, NY, USA) to make stock solutions. Aliquots were stored at −20°C for future use. SKI-I stock solution was diluted in growth medium to a final concentration of 5μm for cell treatment. Cells were incubated with the drug solution 24 hours prior to experiments and serum starved overnight.
B. Cell Seeding of Device
In order to seed cells, devices were sterilized by 70% ethanol and exposed to UV overnight. Cells were harvested, suspended in serum-free media and passed through a cell strainer, Partec CellTricks (Sysmex, IL, USA), to remove cell aggregates and obtain single cell suspensions. Three separate experiments were performed; migration of serumstarved control cells towards media without serum (−FBS), media with 10% serum (+FBS), and serum-starved SKI-I treated cells towards media with 10% serum (SKI-I + FBS). Based on the corresponding experiments, growth medium containing zero, 2.5%, 5%, or 10% FBS was loaded into the bottom chamber of the device as a chemoattractant for serum starved cells. The cells (50,000 cells/ 200μl) in serumfree media were introduced on the top of the membrane and devices were incubated at 37°C in a humidified 5% CO 2 incubator.
C. Cell Viability Assay
At the end of each experiment, a viability assay was performed by tagging dead cells on top of the membrane using Ethidium Homodimer-1 (EthD-1) (component B in Live/Dead viability kit for mammalian cells) (Life Technologies, NY, USA) at a final concentration of 2μm. Fluorescent images were acquired using a Zeiss Axio Imager (Germany). For each device, a representative field of view was imaged and live (green cells previously tagged with CMFDA tag) and dead cells (red) were counted using the free public domain NIH image processing software, ImageJ. Viability for −FBS, +FBS, and SKI-I+ FBS experiments were measured at 87.69±2.65%, 89.98±2.76%, and 83.67±2.36% respectively.
D. ImageJ analysis
ImageJ was used to analyze the acquired images. Initially, the "Subtract Background" function was implemented on the images to eliminate the background effects. Images were converted to binary formats using the "Threshold" and "Make Binary" tools in ImageJ. The "Particle Analyze" tool was used to create final masks for cell migration quantification. Artifacts and showing pores which did not contribute to the actual cell migration were removed by adjusting a size threshold of 100 pixels in the particle analyze tool. The migration of cells in each condition was reported based on the total pixel area of the dark spots.
E. Statistical Analysis
Cell migration rate was expressed as mean with the standard error of the mean (SEM). One-way ANOVA with Tukey's honest significant difference (JMP Software) was performed to find significant difference between different assays. Differences were considered statistically significant for ( * p< 0.01) with level of significance α = 0.05.
IV. RESULTS
A. Cell Migration Classification by Chemoattractant
Cell migration of cancer cells, MDA-MB-231, was verified under different drug and chemoattractant treatment conditions. In this regard, three separate experiments were performed; migration of serum-starved control cells towards media without serum (−FBS), media with 10% serum (+FBS), and anti-tumor drug (SKI-I) treated cells towards media with 10% serum (SKI-I + FBS). Based on the corresponding experiments, growth medium containing zero, 2.5%, 5%, or 10% FBS was loaded into the bottom chamber of the device as a chemoattractant for serum starved cells. The cells (50,000 cells/ 200μl) in serum-free media were introduced on the top of the membrane and devices were incubated at 37°C in a humidified 5% CO 2 incubator. Fig. 3a shows images acquired from the underside of the membrane for different experiments at 2, 6, and 12-hour timepoints. Cell migration was observed by imaging the bottom side of the porous silicon membrane using a Zeiss Axio Observer.Z1 inverted epifluorescence microscope (Germany) with a 20X objective lens and imaged using a Zeiss AxioCam MRc camera (Germany). In order to obtain an overall image of the membrane, 154 frames were obtained and stitched together using the stitching utility of the Zen software. Images were acquired at 2, 6, and 12-hour time points (Fig. 3a) . Images were processed using ImageJ as described previously (Fig. 3b) . Fig. 3c shows the migration rate of the cancer cells under different drug treatment and chemoattractant conditions. Random movement and migration of the cells in the absence of a chemical gradient was studied by creating a serumfree environment above and below the membrane (−FBS experiment). Cells showed low migration after 12 hours since there was no serum available to activate a migration response in the cells. However, once the serum-free media below the membrane was replaced with media containing 10% FBS at the 12-hour time-point, it was evident that a large number of cells had migrated and attached to the other side of the membrane. This phenomenon demonstrates the effective creation of a chemical gradient across the membrane and the ability of MDA-MB-231 cells to migrate through this membrane in the presence of such a gradient. Moreover, the random migration of cells which may interfere with the actual migration response caused by a chemoattractant was low in this platform. Our speculation is that since the membrane is thicker than the conventional membranes, two events will take place: 1) only the most aggressive cells are able to cross the 30μm distance across the membrane, 2) an effective serum gradient is created across the membrane thickness. This is evident by the first trial of experiments (Figure3.a, first row of images). During the first 12 hours of serum free media, no migration was observed since no serum was available to create a migration response. In addition, when serum was added to the bottom chamber, cells sensed this chemical change and migrated to the other side of the membrane over the course of the next 12 hours. Hence, further experiments were carried out to verify the function of this device to distinguish the migration behavior between normal and drug treated cells.
Migration of the untreated cells in the presence of a serum gradient (+FBS experiment) was low at the 2-hour timepoint (Fig. 3a) . As time progressed, a clear distinction in the migration was observed at the 6-hour time-point. After an additional 6 hours, the migration and attachment of cells to the bottom side of the silicon membrane was evident as shown in Fig. 3a . In contrast, migration of the SKI-I treated cells showed no progress even after 12 hours. This can be an indication that the drug has affected the cells, limiting their motility and migration and making it impossible for them to get into the pores and move to the other side of the silicon membrane. Based on this observation, the fabricated device can be used to monitor and distinguish between drug treated and non-treated cells. The devices were re-used for the next experiment with thorough cleaning. First, all the media was taken out and trypsin was added and incubated at 37°C in order to lift off any adhered cells to the various surfaces. Then, organic wastes were completely removed by nanostrip from inside the pores. The devices were rinsed and immersed in DI water, dried, and cleaned by oxygen plasma. Each device was examined under the microscope individually to ensure no residue was left on the device from the previous run.
B. Chemoattractant Gradient Profile Induced Migration
Furthermore, we investigated the migration of cancer cells under different chemical gradient profiles. For this purpose, FBS at the concentrations of 2.5%, 5%, and 10% was loaded into the microchannel and the migration rate of breast cancer cells was quantified (Fig. 4) . Fig. 4b shows the migration rate of cancer cells under different chemoattractant concentration gradients. It can be concluded that there is higher migration rate for the devices filled with 10% FBS compared to the devices filled with 2.5% and 5% FBS and an increase in serum concentration results in higher migration.
V. DISCUSSION
Cell migration plays a key role in biological processes such as embryonic development, immune response, woundhealing, angiogenesis, and cancer metastasis. Evaluation of the migration behavior of cells in a controlled environment is of interest to researchers as it can expand knowledge of the signaling pathways involved in these events and the modulation of chemotactic response of cells by pharmaceutical agents. Commercially available Boyden chambers provide end point analysis of cell migration via a one-time use polycarbonate membrane housed inside a culture plate which needs to be post-processed (i.e. fixing and staining) to provide final results.
The fabricated micro-Boyden chamber migration assay in this work is composed of a porous silicon membrane and microfluidic channels on a single silicon substrate bonded to a glass enclosing which enables real-time analysis of cell migration using a microscope. Moreover, no post processing of the silicon membrane is needed; it can be cleaned at the end of each experiment and reused in contrast to the one-time use polycarbonate membranes. Using a silicon substrate, one can take advantage of readily available fabrication methods in the semiconductor industry to upscale the production of this platform. Taking advantage of these fabrication techniques, it is also possible to create different pore sizes and pore densities on a single membrane whereas such an option is not available in the conventional Boyden chamber assay.
This work furthermore utilizes DRIE to fabricate a deep microfluidics-enabled micro-channels with porous thinmembrane on a single silicon wafer with control on the membrane thickness. Since deep etching of the backside of the microchannel defines the thickness of the membrane, it is vital to achieve a uniform etch profile in order to fabricate the membrane with minimal thickness variation across the area that encloses the pores. Non-uniform etching will result in faster etching of the channel area than the well area which will leave the channel area thinner. If this is not checked, it might result in complete removal of the channel during the etching process to reduce the membrane thickness. Furthermore, a non-uniform etch profile will inadvertently produce a high level of variation on the membrane thickness across the wafer resulting in fewer usable devices. Typically, increasing the etch rate alleviates the non-uniform etching problem. We explored the effect of several parameters that affect the etch uniformity across the devices and the wafer. Reducing SF 6 etch time from 6 secs to below 4 secs in the time-multiplexed DRIE etch recipe, dramatically reduced the etch uniformity. It caused a severe reduction in etch rate on the device, especially on the outer side of the wafer. In such cases, some of the devices at the center of the wafer were etched and met the desired membrane thickness requirement, while the pores on devices at the corners were not yet visible from the channel on the backside. The reduced etch rate also caused a non-uniform membrane with a groove-shaped pattern. The inductively coupled plasma (ICP) power, low frequency (LF) power, and temperature may also be adjusted to increase the etch rate and improve uniformity. Since the wafer was glued to a dummy wafer, temperature was not elevated and kept at 0°C as the photoresist glue was not a good heat conductor and increased temperature might damage the contact between the two wafers. Excessive etch rate during the final phase of the etching (last 10μm) was also avoided to precisely determine the membrane thickness. Our group's previous research work has shown the effect of DRIE on scalloping effect [25] , [26] . We have tried to minimize the effect of scalloping and reduce the negative and positive profiles on the sidewalls based on these works. It is difficult to observe and quantify the effect of scalloping on cell migration and viability, as the cells are stuck inside the pore when facing these features and our imaging technique only shows the top and bottom of the surface.
SKIs are a class of drugs with anti-tumor therapeutic potential due to their ability to inhibit tumor growth by intercepting the sphingosine kinase pathway [23] . They have been shown to have anti-proliferative effect on a variety of tumor cell lines including breast cancer cells [24] . We used the drug SKI-I to treat a highly metastatic cell line, MDA-MB-231, and used this as a model to test the working-principle of our microfluidic migration assay. Our results confirm that SKI-I causes MDA-MB-231 breast cancer cells to become apoptotic and greatly diminishes their migration through the pores in the silicon membrane. Hence, this assay is suitable for evaluating the effect of pharmaceutics and other stimuli on the migration behavior of cells. In addition, different concentrations of serum were used as a chemoattractant to study the applicability of this platform in distinguishing between different serum concentrations and effectively establishing a chemical gradient across the membrane. The results confirm that the cell migration increases with increased serum concentration and the platform is successfully able to maintain the chemical gradient after a relatively long period of time. We have performed zone exclusion assay as our own reference to both monitor the effect of the drug on the cells and to provide a comparison between a conventional method and the presented work (please see the supplementary document).
The developed platform lends itself to the incorporation of improvements that will expand its functionality. For instance, a biocompatible hydrogel can be introduced into the top chamber to create a physiologically relevant model for cell invasion. The addition of electrodes on the bottom side of the membrane, will enable automated label-free measurements of cell migration through bio-impedance sensing. The integration of the microchannels with porous membrane also can be used to improve microfluidic circulation and create gradient profiles across the membrane. Furthermore, the employment of multiple stages of such blocks can result in high throughput cell migration screening based on different candidate-drug treatment plans.
VI. CONCLUSION
In this work, we have presented the fabrication of a siliconbased device for cell migration analysis as an alternative to conventional Boyden chamber assays. This platform integrates a porous membrane with a chemoattractant reservoir and microchannels in a single silicon wafer, reducing the number of components in a conventional Boyden chamber assay. Characterization and optimization of the microfabrication techniques with a focus on the optimization of the deep reactive ion etch parameters are presented to create porous silicon membranes with minimum thickness variance across a single membrane and between different membranes on a wafer, while controlling the pore etch rate and avoiding under/over-etching of the pores.
The experimental results obtained from this device demonstrate its capability to detect migration towards serum in MDA-MB-231 cells. This functionality was emphasized by the fact that the cells exhibit very low migration towards serum-free media, whereas when serum was added to the same media, cells migrate to the underside of the membrane after 12 hours of no migratory activity. Moreover, the migration of drug treated cells was studied using this device. SKI-I treated cells showed very low -close to zero-migration towards serum on this platform, exhibiting the future potential of this device to survey other potential drug treatment plans. Furthermore, this device showed to be capable of distinctively quantifying the cell migration when a chemoattractant gradient profile was formed in the micro-well (2.5-5% vs 10%).
The implementation of this assay on a silicon substrate is beneficial for future modifications such as creating gradient profiles of the size and/or distribution of the pores, since the fabrication techniques utilized in this work are highly controllable and customizable. Additionally, the compatibility of silicon with microfabrication techniques will enable the integration of electrodes and other sensing elements on this platform for label-free detection of cell migration. Furthermore, microfluidics and microchannels on this device can be easily modified to create the desired chemical gradient profiles. In future, we hope to further miniaturize this platform to reduce the amount of reagents and samples needed while providing a means for high throughput assays. In addition, we will enhance the functionality of this device by adding electrodes and creating a label-free method for cell migration sensing and test other drug treatment plans with this enhanced platform. 
